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Abstract: Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized 
by an elevated pulmonary arterial pressure and vascular resistance with a poor prognosis. 
Various pulmonary and extrapulmonary causes are now recognized to exist separately from the 
idiopathic form of pulmonary hypertension. An imbalance in the presence of vasoconstrictors 
and vasodilators plays an important role in the pathophysiology of the disease, one example 
being the lack of prostacyclin. Prostacyclin and its analogues are potent vasodilators with 
antithrombotic, antiproliferative and anti-inflammatory qualities, all of which are important 
factors in the pathogenesis of precapillary pulmonary hypertension. Iloprost is a stable 
prostacyclin analogue available for intravenous and aerosolized application. Due to the severe 
side effects of intravenous administration, the use of inhaled iloprost has become a mainstay 
in PAH therapy. However, owing to the necessity for 6 to 9 inhalations a day, oral treatment 
is often preferred as a first-line therapy. Numerous studies proving the efficacy and safety of 
inhaled iloprost have been performed. It is therefore available for a first-line therapy for PAH. 
The combination with endothelin-receptor antagonists or sildenafil has shown encouraging 
effects. Further studies with larger patient populations will have to demonstrate the use of 
combination therapy for long-term treatment of pulmonary hypertension.
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Pulmonary hypertension
Pulmonary hypertension (PH) is an uncommon disease with a progressive course and 
poor prognosis. It is characterized by an elevated pulmonary arterial pressure exceeding 
25 mmHg at rest.1 The increase of pulmonary vascular resistance by different causes 
induces a right heart overload finally leading to right heart failure and death.
Vasoconstriction, in situ thrombosis in small arteries, and vascular remodeling by 
proliferation of smooth muscle cells with intimal fibrosis, medial hypertrophy, and 
adventitial thickening are major histopathological structural features of pulmonary 
vasculopathy.2
Underlying causes of PH have recently been summarized in the Venice classifica-
tion (see Table 1).3 Without treatment the median survival of patients with idiopathic 
pulmonary hypertension (IPAH) from the time of diagnosis is 2.8 years.4
This review highlights the role of prostacyclin in the pathophysiology of pulmonary 
arterial hypertension (PAH) and focuses on inhaled iloprost as a treatment for the 
various entities of PH. In addition, the role of iloprost for the control of acute PAH 
during surgery will be discussed.Vascular Health and Risk Management 2009:5 466
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For the purpose of this review, we will refer to the Venice 
classification only, as further variations discussed recently 
have not yet been published officially. The term “primary 
pulmonary hypertension” used in previous classifications 
has been renamed and defined more precisely in the Venice 
classification of 20033 and includes IPAH and familial PAH 
since that time.
Pathophysiology
In healthy subjects a balance of dilators and constrictors of 
the pulmonary vasculature results in a normal vascular tone 
in pulmonary arteries. The vessel’s smooth muscle layer 
maintains a state of predominant relaxation.
Prostacyclin (PGI2) – a metabolite of arachidonic acid – is 
endogenously produced by PGI2 synthase and released from 
pulmonary endothelial cells. It mediates vasodilatory 
effects on pulmonary arteries and systemic circulation by 
relaxation of smooth muscles and prevention of platelet 
aggregation due to an increasing intracellular concentration 
of cyclic adenosin monophosphate (cAMP).5 In contrast, 
thromboxane6 – produced by thromboxane synthase from 
arachidonic acid in platelets – mediates vasoconstriction and 
platelet aggregation.
In PAH, vascular remodeling and vasoconstriction 
are determined by an imbalance of the intracellularly 
synthesized factors.7 Experiments in rats exposed to 
monocrotaline and in hypoxic mice developing PAH 
have shown increased PGI2 synthase expression in the 
lung, partially antagonizing the rise in pulmonary arterial 
pressure.8,9 A deficiency of PGI2 synthase in remodeled 
pulmonary vasculature has been reported in patients suf-
fering from severe PAH.10 Accordingly, exogenous PGI2 
benefits patients with PAH by antagonizing the effects of 
vasoconstrictors such as thromboxane A2 and serotonine, 
which are increased in endothelial cells11 causing platelet 
activation and thrombosis.12 Prostacyclin also possesses 
positive inotropic effects resulting in an acutely increased 
cardiac output.13 Long-term improvements of cardiac out-
put may in contrast be caused by anti-remodeling effects 
of PGI2.14
Since the decrease of endogenous PGI2 plays an important 
role in the pathogenesis of pulmonary arterial hypertension, 
the administration of exogenous PGI2 and derivatives has 
become an area of intense investigation for more efficient 
therapies for patients with PAH.
Prostacyclin and analogues
During the past two decades several PGI2 derivatives have 
been synthesized and their effects on pulmonary arterial 
hypertension have been studied. Chronically intravenously 
administered epoprostenol14 is characterized by a very short 
half-life (6 min) but has a significant beneficial effect on 
patients with IPAH and scleroderma-associated PAH. The 
obligatory iv line, however, is prone to cause severe compli-
cations such as exit-site infections, deep venous thrombosis, 
catheter displacement, and pneumothorax.15,16 Therefore, 
PGI2 analogues with different physical conditions and half-
lives delivered by alternative routes have been developed. 
Iloprost is a more stable analogue of PGI2 with a longer 
half-life approaching 30 minutes and similar effects on 
hemodynamics compared to epoprostenol but still burdened 
with complications of its way of delivery.17 Subcutaneously 
infused trepostinil with a half-life of 3 hours has led to 
improved exercise capacity and improved hemodynamics 
in patients with IPAH and PAH associated with collagen 
vascular disease.18 However, side effects such as pain and 
induration at the infusion-site, headache, nausea, rash, and 
jaw pain are complications that are not rare. The first orally 
Table 1 Venice classification of pulmonary arterial hypertension3
Group 1: Pulmonary arterial  
hypertension (PAH)
idiopathic pulmonary hypertension (iPAH), familial PAH, associated 
with other diseases (eg, collagen vascular diseases, portal hypertension, 
congenital shunts, HiV infection, drugs and toxins), persisting PAH of the 
newborn, pulmonary venoocclusive disease, capillary hemangiomatosis
Group 2: Pulmonary venous  
hypertension
Left-sided atrial/ventricular heart disease, left-sided valvular  
heart disease
Group 3: PAH associated with  
hypoxemia/COPD
For example, interstitial lung diseases, chronic obstructive pulmonary 
diseases, sleep-disordered breathing, alveolar hypoventilation disorders
Group 4: PAH due to chronic  
thrombotic or embolic disease
Pulmonary embolism, thromboembolic obstruction of proximal or distal 
pulmonary arteries (eg, by foreign bodies, parasites, tumors, and so on)
Group 5: Miscellanous underlying  
diseases
For example, sarcoidosis, histiocytosis X, lymphangiomatosis, compression 
of pulmonary vesselsVascular Health and Risk Management 2009:5 467
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active PGI2 analogue, beraprost, had no significant effect on 
hemodynamics in patients with PAH in long-term studies19,20 
but has been shown to prolong survival in PAH patients, and 
to improve exercise capacity.21 However, its use is limited 
by prostanoid typical side effects and diarrhea.
inhaled iloprost
For years, continuously administered PGI2 and analogues have 
been used successfully to improve pulmonary hemodynamics 
and long-term prognosis in PAH patients. However, the 
development of tolerance and serious side effects of this 
treatment demonstrated the need for another route of 
application.
An alternative way of administration of PGI2 has therefore 
been developed with aerosolized iloprost through inhalation. 
This PGI2 analogue possesses similar vasodilative potency 
and efficacy profile compared with epoprostenol leading to 
the same intracellular effects after binding to the prostaglan-
din receptor.22 Iloprost remains stable at room temperature 
and in ambient light at pH 7.4 and offers a longer half-life 
(20–25 min23) compared to aerosolized PGI2 or epoprostenol. 
Side effects, however, are very similar. The small aerosolized 
particles (median diameter 0.5–3 µm) are deposited in the 
lung parenchyma during tidal breathing.24,25 Intra-acinar 
pulmonary arteries closely surrounded by alveolar surfaces 
are able to be dilated by alveolar PGI2 deposition. However, 
6.5 to 9.4 minutes post inhalation the effect of inhaled 
iloprost is terminated by β-oxidation resulting in an inactive 
metabolite.26,27 It is therefore necessary to inhale iloprost with 
specialized nebulizers 6 to 12 times a day.28 For practical 
purposes, the number of inhalations for long-term treatment 
is usually recommended with 6 to 9 times per day. However, 
powerful devices have made it possible to reduce the time 
used for inhalation from 15 by jet ventilators to 4 minutes 
by ultrasonic nebulizers.24 A common dosage regimen starts 
with 2.5 µg per inhalation, and will be increased to 5 µg per 
inhalation if tolerated well.
Acting locally, inhaled iloprost selectively dilates 
pulmonary arteries. Systemic side effects are thus greatly 
reduced in comparison to intravenously or subcutaneously 
administered drugs.29 Given the role of the PGI2 receptor 
in the pathophysiology of PAH and the in vivo effects of 
PGI2 and its derivates inhaled iloprost has become a potent 
therapeutic option to treat patients with precapillary PH.
Inhaled iloprost for PAH (group I)
The first study demonstrating a favorable effect of inhaled 
iloprost in patients with PAH was published as early as 
1996 by Olschewski et al.22 This group had demonstrated 
a vasodilative effect of inhaled PGI2 in patients with 
ARDS before.30 In addition, hemodynamic effects have 
also been reported in dogs with hypoxia-induced PH.31 
In 6 patients with idiopathic pulmonary arterial hyperten-
sion and PH associated with CREST syndrome 100 µg 
of PGI2 (and iloprost in one patient) were aerosolized in 
6 to 9 doses for 15 minutes each. Acute and long-term 
beneficial effects on hemodynamics were demonstrated. 
In 1999, 8 patients with PH accompanying lung fibrosis 
exhibited significant benefit to aerosolized PGI2 suggesting 
a vasoconstrictive component in the pathophysiology of 
this clinical situation.32 In both studies effects of the inhaled 
PGI2 analogon iloprost lasted longer than effects after the 
aerosolized PGI2.
Short-term effects on exercise capacity and were studied 
by Wensel et al in 2000.33 Exercise duration and ventilation 
(peak oxygen uptake, VE versus VCO2 slope) improved 
significantly after the inhalation of iloprost in 11 patients 
with IPAH and PAH due to morbus Osler. In this study the 
strongest independent predictors of survival turned out to be 
VO2max and peak systolic blood pressure during exercise, 
highlighting the importance of performing cardiopulmonary 
exercise testing for future study assessment.
Hoeper et al compared acute effects of inhaled iloprost 
and nitric oxide.34 The PGI2 analogue iloprost resulted in a 
greater decrease in pulmonary artery pressure and a stronger 
increase in cardiac output. Vasodilatory effects of inhaled 
PGI2 lasted for approximately 60 minutes. However, a maxi-
mum of 9 inhalations of iloprost per day were performed. 
Long-term beneficial effects on pulmonary artery pressure 
and exercise capacity had nevertheless been shown before. 
The authors therefore concluded that an inhibitory effect of 
PGI2 on vasoproliferation existed. They also suggested that 
the number of daily inhalations could be reduced due to this 
additional lasting effect.
This persisting effect of inhaled iloprost in long-term treat-
ment was also published by two groups in 2000. Olschewski 
et al examined 19 patients with PH in an open, uncontrolled, 
multicenter study. After inhaling iloprost for 3 months 
hemodynamic parameters and exercise capacity improved, 
whereas the acute response to iloprost did not change (results 
pre- versus post-inhalation were similar at 3 months).35 In a 
prospective study Hoeper et al36 investigated the effect of 
iloprost on exercise capacity and hemodynamics in 24 patients 
with IPAH of NYHA classes III and IV. Patients received 
6 to 8 inhalations of 100 µg of iloprost per day. Six-minute 
walking distance (6MWD) increased significantly after Vascular Health and Risk Management 2009:5 468
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3 months of treatment. This effect was still maintained at 
12 months. Improvements of hemodynamic parameters were 
also observed. It was suggested, that aerosolized iloprost be 
used for long-term therapy treatment of PH.
These encouraging findings in patients with precapillary 
PH stimulated the launch of a controlled study investigating 
the safety and efficacy of iloprost. The study was termed 
AIR for Aerosolized Iloprost Randomized study. It had been 
designed as a European, randomized, multicenter, placebo-
controlled trial and was finally published by Olschewski et al.37 
Two hundred and three patients with IPAH, inoperable 
chronic thromboembolic PAH and PH associated with 
collagen vascular diseases or appetite suppressants in NYHA 
functional classes III and IV were included. The effects of 
6 to 9 inhalations of 5 µg iloprost per day over a period of 
12 weeks were evaluated regarding a combined end point of 
exercise capacity (increase of 10%) and functional class. 
16.8% of the patients in the verum group versus 4.9% of 
the placebo group achieved the combined endpoint of an 
increased 6MWD and NYHA class improvement without 
clinical deterioration (p = 0.007). Of the iloprost group 
23.8% improved by one NYHA class and 37.6% walked 
at least 10% further than at baseline. In contrast, 12.7% of 
the patients receiving placebo exhibited an improvement in 
NYHA classification, and the 6MWD increased in 25.5% by 
at least 10%. The increase of the 6MWD between the two 
groups did not reach statistical significance, but the improve-
ment in functional class was significantly more frequent 
in the iloprost group (p = 0.03). The 6MWD increased by 
36.5 m at 12 weeks in all patients inhaling iloprost, and the 
increase was even greater in the subgroup of IPAH patients, 
at 58.8 m. Hemodynamic parameters following 12 weeks of 
inhalation of iloprost significantly improved in comparison 
with baseline values (p  0.001).
Common adverse effects were described as cough, 
headache, flushing and jaw pain. In this study serious side 
effects such as syncope, tachycardia, pneumonia and dyspnea 
occurred in 2% to 5% of the patients. Although in this study 
the impact of inhaled iloprost was not compared with the 
effects of alternative PGI2 analogues, efficacy and safety of 
this form of application of iloprost were demonstrated.
Opitz et al studied the effects of inhaled iloprost with 
regards to the long-term tolerability and clinical efficacy in 
76 patients still symptomatic with conventional treatment 
(IPAH, NYHA classes II and III).38 At 12 months, 32 patients 
still remained on monotherapy with iloprost. The rate of 
event-free survival 3 months after starting therapy was 81%, 
53% after 1 year and 13% at 5 years. Overall survival rates 
showed moderate results, with 93% after 3 months, 79% at 
1 year and 49% at 5 years.
Acute hemodynamic effects of inhaled iloprost were 
also analyzed by an in vivo investigation by Fruhwald et al. 
These authors implanted a hemodynamic monitoring device 
into 5 patients with PAH.39 Its sensor was placed in the right 
ventricular outflow tract. Right ventricular pressures were 
recorded. As a result a significant decrease in pulmonary arterial 
pressure was seen following inhalation of iloprost. However, 
this effect lasted only 17 to 48 minutes. Thus, the duration of 
vasodilation caused by inhaled iloprost is significantly shorter 
than previously suggested. Nevertheless, rebound PH with 
hypoxemic periods at night during the interval without inhalation 
were not found by Mereles et al.40 As a cause, the authors men-
tioned a different reaction to a lower heart rate and cardiac output 
at night due to a pre-dominant parasympathic tone. For patients 
who experience nightly rebounds, Domenighetti suggested a 
combination therapy with the vasodilating phosphodiesterase 
inhibitor sildenafil to cover the inhalation break.41
A comparison of the impact of aerosolized versus intravenous 
iloprost was done by Opitz et al42 in patients with severe PAH. 
Similar hemodynamic changes were observed for both routes of 
application. In contrast, pulmonary vasoselectivity was greater 
using inhaled iloprost which is generally recognized to be of 
benefit. Few studies however, did not confirm the advantage 
of aerosolized iloprost over the intravenous application. In one 
study switch from epoprostenol to inhaled iloprost in 3 patients 
was unsuccessful due to development of right heart failure.43 
Another study reported improvement of exercise capacity with 
intravenous iloprost in 16 patients who deteriorated under 
therapy with inhaled iloprost.44
Precapillary PH of classification group I other than IPAH 
has rarely been treated with inhaled PGI2 analogues. Launay 
et al published a study in 5 patients with PH associated to 
CREST syndrome in 2001, demonstrating improvements in 
NYHA functional class and exercise capacity.45 The 6MWD 
increased from 352 ± 48 to 437 ± 56 m (p = 0.06) at 6 months. 
Along these lines Hallioglu et al46 also observed an advantage 
of aerosolized iloprost over intravenous infusion in children 
with PH secondary to congenital heart disease. In this study the 
decrease in pulmonary-to-systemic vascular resistance ratio 
was found to be significantly greater with inhaled iloprost.
Inhaled iloprost for pulmonary 
hypertension of other Venice 
classification groups
Chronic thromboembolic pulmonary hypertension (CTEPH) 
develops within the first 2 years47,48 in approximately 4% Vascular Health and Risk Management 2009:5 469
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of all patients diagnosed with acute pulmonary embolism. 
There have been only scarce reports using aerosolized 
iloprost for the treatment of CTEPH patients. In the 
AIR study37 a subgroup receiving iloprost comprised 33 
patients with CTEPH representing 67% of the patients in 
the “nonprimary pulmonary hypertension” group. Iloprost 
inhalation in this group resulted in beneficial effects 
on exercise capacity and improvement of NYHA class. 
However, in this study separate data for CTEPH patients 
were not mentioned. Kramm et al reported successful 
treatment of residual postoperative PH after pulmonary 
thrombendarterectomy.49 In addition to these studies, 
several case reports on inhaled iloprost in CTEPH have 
been published.50,51
Ulrich et al showed similar pulmonary artery compliance 
in 35 patients with IPAH and 22 with CTEPH performing 
acute vasoreactivity testing with inhalative nitric oxide and 
iloprost.52 The existence of a reversible vasoconstrictive 
component in CTEPH was also suggested in a study 
observing significant acute hemodynamic improvement after 
inhalation of iloprost.53
For patients with PAH classified other than groups I 
and IV (Venice classification) only a few cases have been 
published. A patient with systemic sclerosis and lung fibrosis 
suffering from severe PAH who had contraindications for 
bosentan treatment received inhaled iloprost. Exercise 
capacity and hemodynamics improved54 shortly after 
treatment had been started.
Long-term experiences with novel treatments for 
portopulmonary hypertension have been rare so far. Hoeper 
et al recently observed improved survival rates and greater 
improvements in hemodynamics as well as exercise capacity in 
patients with portopulmonary hypertension on bosentan therapy 
compared to patients with portopulmonary hypertension on 
inhaled iloprost.55
Combination therapies
Owing to the repeated and still somewhat tedious application 
of inhaled iloprost, orally available pharmaceuticals have 
recently been preferred as initial therapy of PH. None of the 
new drugs approved for PH appears to be able to completely 
prevent progress in all cases. For this reason the combination 
of compounds acting via different pathways has been 
investigated by several authors. Inhaled iloprost has been 
combined with either an endothelin-receptor antagonist or 
with a phosphodiesterase (PDE) inhibitor – both specific 
pulmonary vasodilators. Iloprost has also been used in 
combination with dual oral therapy.
Table 2 Selection of studies examining the effect of aerosolized prostacyclin and iloprost in patients with pulmonary arterial hypertension
Patients PH form NYHA Outcome Remarks
wensel et al33 11 iPAH, PAH due
to morbus Osler
iii Acute hemodynamic improvement:
mPAP −5.7 mmHg
PVR −333.2 dyn*s/cm5
CO + 1.1 L/min
VO2max + 1.4 L/min*kg
Olschewski et al35 19 iPAH, secondary
PH, PAH
associated with
connective tissue
disease
improvement of hemodynamics and
exercise capacity after 3 months:
6MwD + 148 m
mPAP −7.5 mmHg
PVR −295 dyn*s/cm5
Open,
multicenter,
uncontrolled
Hoeper et al36 24 iPAH iii, iV improvement of hemodynamics and 
exercise capacity after 12 months:
6MwD + 85 m,
mPAP −7 mmHg
PVR −280 dyn*s/cm5
Olschewski et al37 203 iPAH, CTePH,
PAH associated
to other diseases
iii, iV After 3 months:
6MwD + 36.5 m
postinhalation mPAP −4.6 mmHg
PVR −239 dyn*s/cm5
Multicenter,
placebo-
controlled
Opitz et al38 76 iPAH ii, iii Overall survival 79% at 1 year 
of therapy
Abbreviations: CO, cardiac output; CTePH, chronic thromboembolic pulmonary hypertension; iPAH, idiopathic pulmonary hypertension; mPAP, mean pulmonary artery 
pressure; PAH, pulmonary arterial hypertension; 6MwD, 6-minute walk distance; PVR, pulmonary vascular resistance;   VO2max, maximum oxygen consumption.Vascular Health and Risk Management 2009:5 470
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In 2001 Schermuly et al described an additive vasodilative 
effect of PGI2 simultaneously applied with PDE inhibitors 
while maintaining lung selectivity in rabbits.56 Wilkens 
et al proposed prolonged and increased vasodilation 
following inhaled iloprost when the PDE-5 inhibitor 
sildenafil was added in 5 patients with IPAH. Combining 
the two therapeutic strategies resulted in a significantly 
lower mean pulmonary artery pressure compared to that 
reached by application of each of the single compounds.57 
In a group of 73 patients with PH, 14 deteriorated while 
on iloprost applied by inhalation. Adding sildenafil to 
the existing iloprost therapy improved exercise capacity 
from 256 ± 30 m to 349 ± 32 m (p = 0.002) at 12 months. 
Pulmonary vascular resistance decreased from 2494 ± 256 
to 1950 ± 128 dyn*s/cm5 as early as 3 months after instal-
lation of combination therapy.58
Improvements in exercise capacity (6MWD increased 
by 58 ± 43 m) and maximal oxygen consumption (from 
11 ± 2.3 to 13.8 ± 3.6 mL × min−1 × kg−1) were also reported 
in a series of 20 patients (9 patients on aerosolized iloprost, 
11 patients on oral beraprost) after 3 months of treatment by 
Hoeper et al 200359 adding the endothelin-receptor antagonist 
bosentan.
Seyfarth et al60 observed an increase in exercise capacity 
and a decline of the Tei index, indicating improvements in 
right heart function 6 months after adding inhaled iloprost to 
existing bosentan therapy in 10 patients with IPAH, CTEPH 
and PAH associated with interstitial lung disease. Nine 
patients also improved in NYHA functional class.
The STEP trial included 67 PAH patients of functional 
class NYHA III, receiving either inhaled iloprost or placebo 
in addition to bosentan therapy for a minimum of 4 months.61 
An increase in the postinhalation, 6MWD of 30 m (p = 0.001) 
was reported in the verum group and of 4 m (p = 0.69) in 
the placebo goup compared to baseline values. However, the 
group-adjusted difference of 26 m was achieved with only 
a marginal significance of p = 0.051. 34% of the patients in 
the iloprost group improved in functional class versus 6% 
on placebo (p = 0.002). A significant prolongation of the 
time to clinical worsening was demonstrated using com-
bined instead of mono therapy. In this study the authors 
suggested, that inhaled iloprost is an option for expanding 
monotherapy when necessary, whereas Hoeper et al62 pre-
sented a multi-center study (COMBI trial) in 2006, in which 
adding inhaled iloprost to bosentan failed to show positive 
effects on hemodynamics in 40 IPAH patients. The authors 
discussed the smaller sample size and higher disease severity 
in the COMBI trial as reasons for the difference in outcome 
of these two similarly designed studies. However, the median 
changes in the 6MWD revealed a significant advantage for 
the iloprost group (+25 m) in comparison to the placebo 
group (+5 m).
Unfortunately, all studies investigating the effect of 
a combination therapy have been performed with small 
populations and relatively great heterogeneity in terms of 
forms of PH.
Inhaled iloprost is currently approved for IPAH functional 
class III in Europe by the European Medicine Agency 
(EMEA), whereas it may be used for patients with PAH in 
functional classes III and IV in countries under the law of 
the Food and Drug Administration (FDA) and for PAH as 
well as CTEPH (NYHA III, IV) in Australia.
Anesthesiologic management 
of patients with pulmonary 
hypertension and the role of inhaled 
iloprost
PH represents a major risk factor for an increased perioperative 
mortality regardless of which anesthetic technique is used: 
stress, pain, mechanical ventilation and systemic inflamma-
tion may lead to a further increase of pulmonary pressure with 
the consequence of acute right heart insufficiency and failure. 
Ramakrishna and coworkers identified several independent 
predictors for short-term morbidity and mortality: a history of 
pulmonary embolism, NYHA functional class  II, high-risk 
surgery, and duration of anesthesia 3 hours.63 In his patient 
cohort 42% developed one or more short-term morbid events. 
In this study, the intraoperative use of vasopressors and the 
non-use of nitric oxide were associated with an increased post-
operative mortality. Depending on the underlying disease and 
the kind of surgical intervention, mortality ranges between 7% 
and 24%, especially in cases of emergency interventions.64–66
The perioperative management of patients with severe 
PH should start preoperatively with a multidisciplinary 
approach to optimize the clinical conditions (anesthesiolo-
gist, cardiologist, pulmologist, and surgeon). Preoperative 
evaluation includes echocardiography with special attention 
to the level of right ventricular dysfunction. In selected cases, 
right heart catheterization should be done preoperatively 
to test for responsiveness of the pulmonary vasculature to 
intravenous or inhaled vasodilators. All options to treat PH 
(oxygen, endothelin-antagonists, PDE-inhibitors, intravenous 
or inhaled prostanoids) should be exploited prior to surgery. 
If PH is newly diagnosed, Fox and coworkers recommend 
preoperative therapy with oral sildenafil (50–100 mg).67Vascular Health and Risk Management 2009:5 471
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Preoperative sedation (midazolam) should be reduced 
to a minimum or substituted by psychological care to avoid 
respiratory insufficiency and acidosis.
Both general and regional anesthesia may be used in 
patients with severe PH, none of them has been proven 
superior to the other, but both are risky. In principle, 100% 
oxygen should be used, and acidosis, hypothermia, and 
hypercarbia should strictly be avoided due to their pulmonary 
vasoconstrictive effects.
Epidural anesthesia has been used safely in patients with 
PH for non-cardiac surgery, vaginal delivery, and cesarean 
section.68 Owing to the better hemodynamic stability, spinal 
catheter technique should be preferred over spinal single 
shoot anesthesia.
intraoperative monitoring and treatment 
of pulmonary hypertension
An intra-arterial line for beat-to-beat measurement of arterial 
blood pressure is essential to ensure sufficient myocardial 
perfusion pressure and for frequent blood gas analysis. 
A pulmonary artery catheter is essential for the continuous 
monitoring of mean pulmonary arterial pressure and, if 
necessary, for measurement of pulmonary capillary wedge 
pressure. Using specialized pulmonary arterial catheters, 
continuous monitoring of right ventricular ejection fraction 
is possible (Vigilance;® Edwards Lifesciences). A central 
venous catheter is helpful for monitoring of right ventricular 
preload and necessary for central administration of vasoactive 
drugs. Whenever possible, transesophageal echocardiography 
is an excellent method for visualization of right ventricular 
filling and function.
The challenge for the anesthesiologist is to prevent 
patients from intraoperative PH crisis by optimization of 
oxygenation, analgesia, intravascular volume, ventilation, 
and acid-base status. Nevertheless, an increase of pulmonary 
pressure may occur and should be treated immediately to 
avoid right heart insufficiency and failure.
In all cases with systemic normo- or hypertension, 
intravenous administration of vasodilators is effective to 
reduce both systemic and pulmonary vascular resistance: 
milrinone or PGI2 are established intravenous therapies for 
an effective treatment of PH. Right ventricular preload may 
be reduced by continuous infusion of nitroglycerin or sodium 
nitroprusside.67,69,70 However, intravenous vasodilators should 
be used very carefully to avoid a drop of the mean arterial 
pressure. In case of hypotension, intravenous vasodilators 
may cause worsening of right ventricular perfusion and 
consecutive right ventricular failure.
In PH patients with intraoperative systemic hypotension, 
inhalation of vasodilators is an advantageous alternative to 
reduce pulmonary pressure without negative effects on mean 
arterial pressure and myocardial perfusion. Lung-selective 
vasodilation is possible using nitric oxide, milrinone, PGI2, or 
iloprost (Table 3).69–73 Inhaled iloprost, however, is superior 
to the others in this list, because of its longer half-life, its lack 
of severe side effects and its ease of administration. Kurzyna 
et al74 for instance, describe the use of inhaled iloprost as a 
rescue therapy in 4 patients with deteriorating hypoxemia 
after atrial septostomy probably caused by an oversized 
right-to-left shunt. In desperate cases, a combination therapy 
may augment the vasodilatory effects.75
Postoperative care
For all patients with significant PH postoperative intensive 
care monitoring is obligatory for at least 12 hours. Attention 
should focus on adequate oxygenation and ventilation, moni-
toring of right heart function and mean pulmonary arterial 
pressure, avoidance of acidosis, and adequate treatment of 
pain.
Conclusion
Years of investigation have led to the acceptance of inhaled 
iloprost as a major strategy to be used in precapillary PH. 
The majority of the studies have demonstrated significant 
beneficial effects of inhaled iloprost on hemodynamics, 
exercise capacity and survival. Recently, potent orally 
Table 3 Treatment of intraoperative pulmonary hypertension crisis69
1)  General principles
   a.  Optimization of right ventricular preload
   b.  Reduction of right ventricular afterload
   c.  Stabilization of coronary blood flow
   d. Avoidance of hypoxic vasoconstriction and acidosis
2)  intravenous vasodilators
   a.    Milrinone (25–50 µg/kg Bw bolus, followed by  
0.5–0.75 µg/kg Bw per minute continuous infusion)
   b.    Sodium nitroprusside (0.2–0.5 µg/kg Bw per minute  
continuous infusion)
   c.  Prostacyclin (4–10 ng/kg Bw per minute continuous infusion)
   d.  iloprost (1–3 ng/kg Bw per minute continuous infusion)
3)  Pulmonary selective vasodilation
   a.    iloprost (5–10 µg diluted in 10 mL saline solution, nebulized over 
10 min, repeated every 2–4 hours)
   b.    Prostacyclin (25–50 µg diluted in 50 mL saline solution, nebulized 
over 15 min, repeated every hour)
   c.  Nitric oxide (5–40 ppm continuously)Vascular Health and Risk Management 2009:5 472
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available drugs have been developed that work well as 
first-line PAH therapeutics. Due to its more complex 
application involving 6 to 9 inhalations a day inhaled iloprost 
is no longer the first choice in PAH therapy. However, it is 
clearly a very valuable option if oral treatment is impossible or 
for combination therapy if monotherapy does not suffice.
Aerosolized iloprost clearly has an advantage over 
intravenously or subcutaneously administered PGI2 analogues 
with only limited side effects due to targeted delivery 
resulting in a selective pulmonary effect. Aerosolized iloprost 
may therefore be given to patients with acute hemodynamic 
instability. Improvements in the application mode may be 
hoped for such as the development of longer stable PGI2 
analogues and more potent and faster delivery units.
The wide use of aerosolized iloprost is also reflected in 
its use for vasoreactivity testing in patients with PH. In that 
respect, iloprost proved to be even more potent than NO.76
The combination with other vasodilators has resulted in 
encouraging effects on hemodynamics and tolerance. Further 
studies with higher numbers of patients will demonstrate if 
combined strategies including inhaled iloprost are in fact 
appropriate for long-term PAH treatment.
Beside the key study (AIR) to prove inhaled iloprost as 
a potent therapeutic for patients with precapillary PH with 
limited functional capacity (NYHA III, IV), all other studies 
were non-controlled, but suggested effectiveness, tolerability, 
and longer survival.
Patients with functional classes NYHA II and III exhibited 
more benefit on monotherapy with iloprost than classes IV 
and therefore these patients appear to be especially suited for 
inhaled iloprost. Further evaluation might focus on early com-
bined treatment involving inhaled iloprost and oral treatment 
in NYHA class II patients but will also have to evaluate all 
combinations used for pulmonary arterial hypertension.
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